Ionis Pharmaceuticals Inc (NASDAQ: IONS) on Monday, soared 3.07% from the previous trading day, before settling in for the closing price of $46.89. Within the past 52 weeks, IONS’s price has moved between $35.95 and $54.44.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 13.97% over the past five years. The company achieved an average annual earnings per share of -40.67%. With a float of $134.04 million, this company’s outstanding shares have now reached $144.34 million.
Let’s look at the performance matrix of the company that is accounted for 927 employees. In terms of profitability, gross margin is 97.22%, operating margin of -44.85%, and the pretax margin is -43.37%.
Ionis Pharmaceuticals Inc (IONS) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Ionis Pharmaceuticals Inc is 8.33%, while institutional ownership is 97.10%. The most recent insider transaction that took place on Aug 29 ’24, was worth 16,428. In this transaction EVP, Chief Development Officer of this company sold 331 shares at a rate of $49.63, taking the stock ownership to the 84,823 shares. Before that another transaction happened on Aug 28 ’24, when Company’s EVP, Chief Development Officer sold 320 for $49.16, making the entire transaction worth $15,731. This insider now owns 85,154 shares in total.
Ionis Pharmaceuticals Inc (IONS) Performance Highlights and Predictions
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -1.03 earnings per share (EPS) for the period topping the consensus outlook (set at -1.04) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -40.67% per share during the next fiscal year.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Trading Performance Indicators
Ionis Pharmaceuticals Inc (IONS) is currently performing well based on its current performance indicators. A quick ratio of 7.51 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.53, a number that is poised to hit -1.13 in the next quarter and is forecasted to reach -3.43 in one year’s time.
Technical Analysis of Ionis Pharmaceuticals Inc (IONS)
Ionis Pharmaceuticals Inc (NASDAQ: IONS) saw its 5-day average volume 1.38 million, a positive change from its year-to-date volume of 1.2 million. As of the previous 9 days, the stock’s Stochastic %D was 36.10%. Additionally, its Average True Range was 1.62.
During the past 100 days, Ionis Pharmaceuticals Inc’s (IONS) raw stochastic average was set at 75.53%, which indicates a significant increase from 49.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 33.36% in the past 14 days, which was lower than the 36.00% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $48.03, while its 200-day Moving Average is $45.96. Nevertheless, the first resistance level for the watch stands at $49.44 in the near term. At $50.55, the stock is likely to face the second major resistance level. The third major resistance level sits at $52.02. If the price goes on to break the first support level at $46.86, it is likely to go to the next support level at $45.39. Assuming the price breaks the second support level, the third support level stands at $44.28.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Key Stats
Market capitalization of the company is 7.07 billion based on 145,965K outstanding shares. Right now, sales total 787,650 K and income totals -366,290 K. The company made 225,250 K in profit during its latest quarter, and -66,270 K in sales during its previous quarter.
